🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

US House bill would curb genetic info sharing with China's Wuxi Apptec, BGI

Published 01/26/2024, 11:24 AM
Updated 01/26/2024, 12:51 PM
© Reuters. FILE PHOTO: The logo of Chinese gene firm BGI Group is seen at its building in Beijing, China March 25, 2021.  REUTERS/Carlos Garcia Rawlins/File Photo

By Karen Freifeld

(Reuters) - A congressional committee focused on China has introduced a bill that would restrict federally funded medical providers from allowing China's BGI Group, WuXi Apptec and other biotech companies from getting genetic information about Americans.

The House select committee on China, led by Republican congressman Mike Gallagher, said the legislation unveiled on Thursday is aimed at BGI Group and its subsidiaries MGI and Complete Genomics, along with WuXi Apptec, according to a statement.

Shares of Wuxi Apptec fell 10% in trading in China following news of the bill overnight. The company said on Friday that company-related content in a proposed U.S. legislation on bio-security is not appropriate or accurate.

The company is "closely watching" the development of the bill, it said in a filing to Shanghai bourse, adding that its business development will not pose any security risk for any country.

BGI Group said in a statement that it supports protecting personal data, but the legislation "which will effectively drive BGI from the U.S. market will not accomplish this goal." The company added that in the U.S. it does not collect patient samples or have access to personal or genetic data.

Similar legislation was introduced in the Senate. The bill has a long path forward before potentially becoming law.

"Closing this loophole is the first step in protecting the American bioeconomy and our national security, and ensuring our genomic data is kept safe and secure,” said Democratic committee member Raja Krishnamoorthi.

The legislation would establish a framework to prevent U.S. taxpayer dollars going to biotech entities of concern, he added.

It would restrict the government's Medicare and Medicaid health programs from using BGI, which would slash its market in the U.S., a person briefed on the bill said.

© Reuters. FILE PHOTO: The logo of Chinese gene firm BGI Group is seen at its building in Beijing, China March 25, 2021.  REUTERS/Carlos Garcia Rawlins/File Photo

Units of BGI Group appear on a U.S. Department of Commerce export control list over allegations that they pose a "significant risk" to contributing to Chinese government surveillance.

Reuters also has reported that BGI was collecting genetic data from millions of women for sweeping research on the traits of populations, and collaborates with China's military.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.